查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1732843

人類生長激素市場－全球產業規模、佔有率、趨勢、機會和預測（按產品、應用、配銷通路、地區和競爭細分，2020-2030 年）

Human Growth Hormone Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球人類生長激素 (HGH) 市場價值為 62.1 億美元，預計到 2030 年將以 13.29% 的強勁複合年成長率成長。製藥和生物技術產業內這個快速發展的領域以使用生長激素（一種由腦下垂體產生的關鍵激素）為中心，以支持生長、發育和代謝功能。主要成長動力包括生長激素缺乏症（GHD）盛行率的上升，尤其是在兒童中，以及老齡人口對 HGH 療法的興趣日益濃厚，以解決與年齡相關的荷爾蒙下降問題。除了已批准的醫療應用外，HGH 還因其潛在的抗衰老和健康益處而被人們所探索，這進一步擴大了其需求。該市場擁有廣泛的產品種類，包括重組人類生長激素 (rhGH) 和生物相似藥，其中注射劑型佔據主導地位。戰略研發計劃、監管部門的批准以及製藥公司之間的合作正在塑造市場的競爭格局。然而，可近性問題和高昂的治療費用仍然是挑戰，同時也存在對出於增強目的的標籤外使用的道德擔憂。

市場概覽
預測期 2026-2030
2024年市場規模 62.1億美元
2030年市場規模 131.6億美元
2025-2030 年複合年成長率 13.29%
成長最快的領域 網路藥局
最大的市場 北美洲

關鍵市場促進因素

生長激素缺乏症（GHD）盛行率不斷上升

主要市場挑戰

高成本

主要市場趨勢

生物相似藥

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球人類生長激素市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按產品（長效、其他）
    • 依應用（生長激素 (GH) 缺乏症、特納氏症、特發性身材矮小症、普拉德威利症候群、小於胎齡兒、其他）
    • 依配銷通路（醫院藥局、零售藥局、網路藥局、專業藥局）
    • 按地區（北美、歐洲、亞太、南美、中東和非洲）
    • 按公司分類（2024）
  • 產品市場圖
    • 按產品
    • 按應用
    • 按配銷通路
    • 按地區

第6章：北美人類生長激素市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲人類生長激素市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區人類生長激素市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲

第9章：南美人類生長激素市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲人類生長激素市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購
  • 產品開發
  • 最新動態

第 13 章：波特的分析

第 14 章：PESTEL 分析

第 15 章：競爭格局

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Sandoz International GmbH (Novartis AG)
  • Genentech, Inc. (Roche)
  • Merck KGaA
  • Ferring Pharmaceuticals
  • Ipsen Pharma
  • Teva Pharmaceutical Industries, Ltd.

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 16134

The Global Human Growth Hormone (HGH) Market was valued at USD 6.21 billion in 2024 and is projected to grow at a robust CAGR of 13.29% through 2030. This rapidly evolving sector within the pharmaceutical and biotechnology industry centers on the use of somatotropin-a crucial hormone produced by the pituitary gland-to support growth, development, and metabolic functions. Key growth drivers include the rising prevalence of growth hormone deficiencies (GHD), especially among children, and increased interest in HGH therapy among the aging population to address age-related hormonal decline. In addition to its approved medical applications, HGH is being explored for its potential anti-aging and wellness benefits, further expanding its demand. The market features a wide range of products, including recombinant human growth hormone (rhGH) and biosimilars, with injectable formulations dominating the segment. Strategic R&D initiatives, regulatory approvals, and collaborations among pharmaceutical companies are shaping the market's competitive landscape. However, accessibility issues and high treatment costs remain challenges, alongside ethical concerns about off-label use for enhancement purposes.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.21 Billion
Market Size 2030USD 13.16 Billion
CAGR 2025-203013.29%
Fastest Growing SegmentOnline Pharmacy
Largest MarketNorth America

Key Market Drivers

Increasing Prevalence of Growth Hormone Deficiency (GHD)

The growing incidence of Growth Hormone Deficiency (GHD) remains a primary catalyst for the Human Growth Hormone (HGH) market globally. GHD, caused by inadequate hormone secretion from the pituitary gland, significantly affects growth, especially in children, and impacts overall health in adults. Current estimates suggest that GHD occurs in 1 out of every 4,000 to 10,000 live births, with a substantial number of adult-onset cases recorded annually. Greater awareness and improved diagnostic tools have enabled earlier detection and intervention, enhancing patient outcomes. Contributing factors include poor nutrition, increased stress, genetic disorders, and medical conditions involving the hypothalamic-pituitary axis. As access to healthcare broadens, more individuals are seeking evaluation and treatment for growth-related disorders, spurring pharmaceutical companies to develop long-acting therapies and improve patient compliance. This growing patient population continues to drive demand for HGH treatment solutions worldwide.

Key Market Challenges

High Cost

Cost remains a significant barrier in the Global Human Growth Hormone (HGH) Market. The complex production process of recombinant human growth hormone (rhGH), involving high-end biotechnological methods and rigorous quality standards, contributes to elevated prices. The long duration of therapy, often lasting several years, further increases the financial burden on patients and healthcare systems. Limited insurance coverage in certain regions and insufficient public health resources exacerbate access issues. As a result, many patients are unable to afford or maintain treatment, especially in lower-income markets. Addressing affordability through cost-effective production and pricing strategies is essential to broaden access to life-enhancing HGH therapies.

Key Market Trends

Biosimilars

The growing presence of biosimilars is a transformative trend in the Global Human Growth Hormone (HGH) Market. These are biologic products designed to closely resemble original rhGH therapies in terms of safety, efficacy, and quality, but at a more accessible price point. Biosimilars undergo stringent regulatory scrutiny and clinical testing to ensure comparable performance to reference drugs. Their introduction promotes market competition, helping to reduce treatment costs and improve patient access. As biosimilar adoption expands, particularly in cost-sensitive regions, their role in the market is increasing. Nevertheless, regulatory approval processes, interchangeability protocols, and manufacturing consistency remain key considerations. Overall, biosimilars represent a promising path toward greater affordability and availability of HGH treatments.

Key Market Players

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Sandoz International GmbH (Novartis AG)
  • Genentech, Inc. (Roche)
  • Merck KGaA
  • Ferring Pharmaceuticals
  • Ipsen Pharma
  • Teva Pharmaceutical Industries, Ltd.

Report Scope:

In this report, the Global Human Growth Hormone (HGH) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Growth Hormone (HGH) Market, By Product:

  • Long Acting
  • Others

Human Growth Hormone (HGH) Market, By Application:

  • Growth Hormone (GH) Deficiency
  • Turner Syndrome
  • Idiopathic Short Stature
  • Prader-Willi Syndrome
  • Small for Gestational Age
  • Other

Human Growth Hormone (HGH) Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Specialty Pharmacy

Human Growth Hormone (HGH) Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human Growth Hormone (HGH) Market.

Available Customizations:

Global Human Growth Hormone (HGH) Market report with the given Market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Types
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Human Growth Hormone Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Long Acting, Others)
    • 5.2.2. By Application (Growth Hormone (GH) Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Other)
    • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy)
    • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.5. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Product
    • 5.3.2. By Application
    • 5.3.3. By Distribution Channel
    • 5.3.4. By Region

6. North America Human Growth Hormone Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Human Growth Hormone Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Human Growth Hormone Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Human Growth Hormone Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Distribution Channel

7. Europe Human Growth Hormone Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Human Growth Hormone Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Human Growth Hormone Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Human Growth Hormone Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Human Growth Hormone Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Human Growth Hormone Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
      • 7.3.5.3. By Product
      • 7.3.5.4. By Application
      • 7.3.5.5. By Distribution Channel

8. Asia-Pacific Human Growth Hormone Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Human Growth Hormone Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Japan Human Growth Hormone Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. India Human Growth Hormone Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Human Growth Hormone Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Human Growth Hormone Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Distribution Channel

9. South America Human Growth Hormone Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Human Growth Hormone Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Human Growth Hormone Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Human Growth Hormone Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Human Growth Hormone Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Human Growth Hormone Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Human Growth Hormone Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. South Africa Human Growth Hormone Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Porter's analysis

14. PESTEL analysis

15. Competitive Landscape

  • 15.1. Novo Nordisk A/S
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
  • 15.2. Eli Lilly and Company
  • 15.3. Pfizer, Inc.
  • 15.4. Sandoz International GmbH (Novartis AG)
  • 15.5. Genentech, Inc. (Roche)
  • 15.6. Merck KGaA
  • 15.7. Ferring Pharmaceuticals
  • 15.8. Ipsen Pharma
  • 15.9. Teva Pharmaceutical Industries, Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer